Skip to Main content Skip to Navigation
Journal articles

Drugging histone methyltransferases in cancer

Abstract : Targeting chromatin-modifying enzymes is a promising strategy for cancer treatment. The antitumor effectivity of compounds inhibiting histone methyltransferases - mainly EZH2 - is currently being tested in phase I/II clinical trials, some of them showing positive results in hematological malignancies and solid tumors of specific mutational background. In this review, we aim at highlighting the recent advances in the field of histone methyltransferase inhibitors and describing the challenges that need to be addressed for their successful implementation in the clinics.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03489962
Contributor : Accord Elsevier CCSD Connect in order to contact the contributor
Submitted on : Thursday, July 21, 2022 - 10:50:59 AM
Last modification on : Tuesday, August 2, 2022 - 4:30:42 AM

File

S1367593119301309.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Citation

Laia Richart, Raphaël Margueron. Drugging histone methyltransferases in cancer. Current Opinion in Chemical Biology, Elsevier, 2020, 56, pp.51 - 62. ⟨10.1016/j.cbpa.2019.11.009⟩. ⟨hal-03489962⟩

Share

Metrics

Record views

13

Files downloads

3